Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.07 Million EUR | 64.46% |
| 2022 | -14.28 Million EUR | -2589.2% |
| 2021 | 574 Thousand EUR | 127.52% |
| 2020 | -2.08 Million EUR | 35.76% |
| 2019 | -3.24 Million EUR | -18.89% |
| 2018 | -2.73 Million EUR | -172.34% |
| 2017 | -1 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.79 Million EUR | 0.0% |
| 2024 Q1 | -1.79 Million EUR | -4.01% |
| 2023 Q2 | -1.63 Million EUR | -100.0% |
| 2023 FY | -5.07 Million EUR | 64.46% |
| 2023 Q3 | -1.72 Million EUR | -5.48% |
| 2023 Q1 | -816.5 Thousand EUR | 79.26% |
| 2023 Q4 | -1.72 Million EUR | 0.0% |
| 2022 Q2 | -10.35 Million EUR | -100.0% |
| 2022 Q4 | -3.93 Million EUR | -100.0% |
| 2022 FY | -14.28 Million EUR | -2589.2% |
| 2022 Q1 | -5.17 Million EUR | -222.79% |
| 2022 Q3 | -1.96 Million EUR | 80.99% |
| 2021 Q2 | 1.89 Million EUR | 0.0% |
| 2021 Q1 | 1.89 Million EUR | 649.56% |
| 2021 FY | 574 Thousand EUR | 127.52% |
| 2021 Q4 | -1.6 Million EUR | 0.0% |
| 2021 Q3 | -1.6 Million EUR | -184.82% |
| 2020 Q2 | -699 Thousand EUR | 0.0% |
| 2020 Q1 | -699 Thousand EUR | 0.0% |
| 2020 FY | -2.08 Million EUR | 35.76% |
| 2020 Q4 | -344 Thousand EUR | 0.0% |
| 2020 Q3 | -344 Thousand EUR | 50.79% |
| 2019 FY | -3.24 Million EUR | -18.89% |
| 2018 FY | -2.73 Million EUR | -172.34% |
| 2017 FY | -1 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -44.343% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 96.563% |
| Adocia SA | -21.16 Million EUR | 76.004% |
| Biophytis S.A. | -17.02 Million EUR | 70.175% |
| Advicenne S.A. | -7.03 Million EUR | 27.777% |
| genOway Société anonyme | 1.56 Million EUR | 423.94% |
| IntegraGen SA | -171.39 Thousand EUR | -2862.678% |
| Medesis Pharma S.A. | -3.95 Million EUR | -28.249% |
| Neovacs S.A. | -8.74 Million EUR | 41.922% |
| NFL Biosciences SA | -3.74 Million EUR | -35.577% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 6514.127% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -60.141% |
| Sensorion SA | -22.06 Million EUR | 76.985% |
| Theranexus Société Anonyme | -6.82 Million EUR | 25.629% |
| TME Pharma N.V. | -6.73 Million EUR | 24.614% |
| Valbiotis SA | -7.36 Million EUR | 31.08% |
| TheraVet SA | -1.57 Million EUR | -223.294% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 75.039% |
| argenx SE | -272.91 Million EUR | 98.139% |
| BioSenic S.A. | -28.77 Million EUR | 82.355% |
| Celyad Oncology SA | -8.44 Million EUR | 39.891% |
| DBV Technologies S.A. | -67.26 Million EUR | 92.451% |
| Galapagos NV | 211.69 Million EUR | 102.399% |
| Genfit S.A. | -28.89 Million EUR | 82.425% |
| GeNeuro SA | -14.75 Million EUR | 65.589% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 66.983% |
| Innate Pharma S.A. | -7.57 Million EUR | 32.919% |
| Inventiva S.A. | -110.42 Million EUR | 95.401% |
| MaaT Pharma SA | -19.71 Million EUR | 74.246% |
| MedinCell S.A. | -25.03 Million EUR | 79.719% |
| Nanobiotix S.A. | -39.7 Million EUR | 87.209% |
| Onward Medical N.V. | -36.18 Million EUR | 85.965% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -51.449% |
| OSE Immunotherapeutics SA | -23 Million EUR | 77.925% |
| Oxurion NV | -18.96 Million EUR | 73.23% |
| Pharming Group N.V. | -9.75 Million EUR | 47.953% |
| Poxel S.A. | -35.09 Million EUR | 85.529% |
| GenSight Biologics S.A. | -26.22 Million EUR | 80.633% |
| Transgene SA | -22.32 Million EUR | 77.257% |
| Financière de Tubize SA | 88.15 Million EUR | 105.761% |
| UCB SA | 343 Million EUR | 101.48% |
| Valneva SE | -101.42 Million EUR | 94.994% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 82.083% |